---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-074915"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-06-17T12:52:16+00:00"
generated_at: "2026-06-17T12:55:10.105684+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2

## Summary
- 6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).
- 9 patients remain on treatment; median follow-up 9.8 months; no new safety signals.
- First patient dosed in TARGET-D 201 Phase 2 registration trial of VS-7375 (KRAS G12D) in second-line mPDAC.
- PanCAN provided $3.8M Therapeutic Accelerator Award in 2022 for RAMP 205 research.

## SEC filing metadata
- accession: 0001104659-26-074915
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-06-17T12:52:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/0001104659-26-074915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-074915
- JSON: https://secwatch.observer/filing/0001104659-26-074915.json
- Plain text: https://secwatch.observer/filing/0001104659-26-074915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.